An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives (Q36164723)

12 August 2017

1 reference

title

An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives (English)

1 reference

12 August 2017

1 reference

Monnier L

1

1 reference

12 August 2017

Benichou M

2

1 reference

12 August 2017

Charra-Ebrard S

3

1 reference

12 August 2017

Boegner C

4

1 reference

12 August 2017

Colette C

5

1 reference

12 August 2017

publication date

1 April 2005

1 reference

12 August 2017

published in

Diabetes and Metabolism

1 reference

12 August 2017

volume

31

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

101-109

1 reference

Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Adherence in diabetes: can we define it and can we measure it?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

A systematic review of adherence with medications for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Standards of medical care in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Utility of casual postprandial glucose levels in type 2 diabetes management

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Global assessment for quality and safety of control in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Carbohydrate metabolism in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Occurrence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycaemic agents: importance of blood glucose monitoring.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Insulin use in NIDDM. Rationale based on pathophysiology of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Self-monitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Quantitation of basal endogenous glucose production in Type II diabetes: importance of the volume of distribution

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Loss of early insulin secretion leads to postprandial hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Thiazolidinediones: metabolic actions in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Sulphonylurea action revisited: the post-cloning era.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

A prospective analysis of the HOMA model. The Mexico City Diabetes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Incretins, insulin secretion and Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Clinical practice. Initial management of glycemia in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970174-X

7 January 2021

10.1016/S1262-3636(07)70174-X

Identifiers

DOI

1 reference

12 August 2017

1 reference